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Abstract
Background: Menwith germline breast cancer 1, early onset (BRCA1) or breast cancer 2,
early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer
(PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to
ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an
international consortium of 62 centres in 20 countries evaluating the use of targeted PCa
screening in men with BRCA1/2 mutations.
Objective: To report the ﬁrst year’s screening results for all men at enrolment in the
study.
Design, setting and participants: We recruited men aged 40–69 yr with germline
BRCA1/2 mutations and a control group of men who have tested negative for a
pathogenic BRCA1 or BRCA2 mutation known to be present in their families. All men
underwent prostate-speciﬁc antigen (PSA) testing at enrolment, and thosemenwith PSA
>3 ng/ml were offered prostate biopsy.
Outcome measurements and statistical analysis: PSA levels, PCa incidence, and tumour
characteristics were evaluated. The Fisher exact test was used to compare the number of
PCa cases among groups and the differences among disease types.
Results and limitations: We recruited 2481 men (791 BRCA1 carriers, 531 BRCA1
controls; 731 BRCA2 carriers, 428 BRCA2 controls). A total of 199 men (8%) presented
with PSA >3.0 ng/ml, 162 biopsies were performed, and 59 PCas were diagnosed (18
BRCA1 carriers, 10 BRCA1 controls; 24 BRCA2 carriers, 7 BRCA2 controls); 66% of the
tumours were classiﬁed as intermediate- or high-risk disease. The positive predictive
value (PPV) for biopsy using a PSA threshold of 3.0 ng/ml in BRCA2mutation carriers was
48%—double the PPV reported in population screening studies. A signiﬁcant difference in
detecting intermediate- or high-risk disease was observed in BRCA2 carriers. Ninety-ﬁve
percent of the men were white, thus the results cannot be generalised to all ethnic
groups.
Conclusions: The IMPACT screening network will be useful for targeted PCa screening
studies in men with germline genetic risk variants as they are discovered. These
preliminary results support the use of targeted PSA screening based on BRCA genotype
and show that this screening yields a high proportion of aggressive disease.
Patient summary: In this report, we demonstrate that germline genetic markers can be
used to identify men at higher risk of prostate cancer. Targeting screening at these men
resulted in the identiﬁcation of tumours that were more likely to require treatment.
# 2014 European Association of Urology. Published by Elsevier B.V.
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Prostate cancer (PCa) is the second most common cancer in
men worldwide and the sixth most common cause of death
[1]. There is a large degree of variation worldwide in both
incidence and mortality because of differences in genetic
background, lifestyle, the availability of screening pro-
grammes, and treatments.
Men with germline mutations in breast cancer 1, early
onset (BRCA1) or breast cancer 2, early onset (BRCA2) genes
have an increased risk of PCa. The relative risk of PCa by
65 yr is estimated at 1.8-fold to 4.5-fold for BRCA1 carriers
[2,3] and at 2.5-fold to 8.6-fold for BRCA2 carriers [4–6]. A
number of retrospective studies consistently report that
BRCA2 carriers present at a younger age with aggressive
disease, higher rates of lymph node involvement, distant
metastasis at diagnosis, and a higher mortality rate
compared with noncarriers [7–12]. While there is debate
about whether there is an increased risk of PCa for BRCA1
carriers, there is increasing evidence that these men also
present with more aggressive disease [7,9,13]. In addition,
BRCA2 mutation status has been confirmed as an indepen-
dent prognostic factor for poorer outcome [7]. Therefore,
targeted screening of BRCA1/2 carriers for earlier detection
may be beneficial.The prostate-specific antigen (PSA) test is the most
effective PCa biomarker currently available; however, its
limitations are well documented. Expert groups have
concluded that data from existing clinical trials—notably
the Prostate, Lung, Colorectal and Ovary screening study
(PLCO) [14] and the European Randomised Study of
Screening for Prostate Cancer (ERSPC) [15]—are insufficient
to recommend routine general population PSA screening.
The main scientific challenge is to differentiate between
menwhowill benefit from screening andmenwhowill not,
reducing overdiagnosis and overtreatment while maintain-
ing benefits (ie, lower mortality).
There is no international consensus on targeting
screening at men at higher risk. There have been a limited
number of studies of screening in men with a family history
of PCa [16–18]. Most of the studies support the use of
targeted screening; however, methodological differences
make it difficult to draw conclusions from these data
[16,17,19–26]. The IMPACT study (Identification of Men
with a genetic predisposition to ProstAte Cancer: Targeted
screening in BRCA1/2 mutation carriers and controls;
www.impact-study.co.uk) is an international, multicentre
study evaluating the role of targeted PSA screening in men
with BRCA1/2 mutations. The aims of IMPACT are to
evaluate the utility of PSA screening, to determine PCa
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biopsy using a PSA threshold of 3.0 ng/ml, to determine
biopsy rates, and to evaluate the characteristics of the
tumours to establish whether PSA screening detects
clinically significant disease in this population compared
with the control group. This analysis reports the results of
the first screening round for all men enrolled in IMPACT
from October 2005 to February 2013.
2. Materials and methods
The IMPACT study design and methods have previously been reported
elsewhere [27,28] and are summarised below (Fig. 1). The protocol was
approved by the West-Midlands Research and Ethics Committee in the
United Kingdom (reference 05/MRE07/25) and subsequently by each
participating institution’s local committee. All participants provide
written consent, and interim analyses are presented to the Independent
Data and Safety Monitoring Committee biannually.
The target sample is 500 BRCA1 mutation carriers and 350 BRCA2
mutation carriers and a control group of 850 men who tested negative
for a pathogenic BRCA mutation in their family. IMPACT has been
powered to detect a twofold increased risk over 5 yr of screening, with
80% power at p < 0.01.
We recruited men aged 40–69 from families with a BRCA mutation
between October 2005 and February 2013. Men were recruited from
cancer genetics clinics from families with known pathogenic BRCA1 or
BRCA2 mutations. Men from these families could enter the study if they
had tested positive or negative for the mutation, or if they were at
50% risk of inheriting amutation but had not yet undergone testing. Men
in the latter group were tested within the study to be allocated to the
appropriate group for analysis, but this result was not fed back to
participants. Men were excluded if they were known to have PCa or if
they had a prior cancer diagnosis with a prognosis of <5 yr. In the Dutch
cohort, men were also excluded if they had prior PSA screening.
ParticipantsunderwentPSA testingat enrolment, and if their PSAvalue
was>3.0 ng/ml, a 10-core transrectal ultrasound–guided prostate biopsy
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Fig. 1 – Study design.
ASAP = atypical small acinar proliferation; PIN = prostate intraepithelial neoplawas recommended. PSA quality assurance wasmeasured on a concurrent
serum sample. All available samples were tested using the ProStatus PSA
Free/Total DELFIA assay at SUS (Malmo¨, Sweden). In addition, in men
undergoing biopsy, serum samples were tested for microseminoprotein
(MSP) and four kallikrein markers (free PSA, intact PSA, total PSA, and
human kallikrein-related peptidase 2 [hK2]). The methods have been
described previously [29,30]. The results from the four kallikrein markers
were combined to create a risk score (Rotterdam score) using a previously
described model [30].
Participants with PSA 3.0 ng/ml will undergo annual PSA screening
for 5 yr, except participants in the Dutch cohort, who are screened
biennially (because of the constraints of the ministerial approval).
Participants with PSA >3.0 ng/ml and a negative biopsy will undergo
annual PSA testing, repeating the biopsy if PSA increases by >50%. All
participants will be followed up for 5 yr to evaluate the cancer
incidence and PCa-speciﬁc mortality and morbidity [27,28].
The local histopathologist at each centre reported the biopsy results
to guide treatment in accordance with local guidelines. The Gleason
score, clinical stage, and classiﬁcation of disease into low, intermediate,
or high risk of metastasis [31] were reported for each case. Central
pathology review was performed by the study pathologist (C.S.F.) to
ensure consistency and standardisation. Prostate core biopsies were
assessed in accordance with International Society of Urological
Pathology guidelines [32] (described previously [10,33]). Whenever
high-grade prostate intraepithelial neoplasia (HG PIN) or atypical small
acinar proliferation (ASAP)was detected, the biopsywas repeatedwithin
3–6 mo.
2.1. Statistical analysis
Statistical analysis was undertaken using SPSS v.21 and Stata 12.0. The
Fisher exact test was used to compare the number of PCa cases detected
among groups and differences among disease types. The PPV of the
biopsy using PSA>3.0 ng/ml in the different groups was compared using
the chi-square test for independence. To compare the mean ages of men
with high PSA levels, t tests were used; p < 0.05 was considered
statistically signiﬁcant. The Wald test was used to test the associationnaire
Biopsy 
(oponal) 
Cancer
A, 
rine 
PSA ≤3
5 yr
tment 
psy 
Annual visits 
5th year 
Cancer
No cancer—annual 
follow-up 
ruited 
 mutaon, 40-69 yr, no 
gnosis for other cancer. 
med consent
sia; PSA = prostate-specific antigen; QoL = quality-of-life.
2481 men recruited to the 
IMPACT study; 
inclusion criteria: 
subject from family with 
known mutaon, 40–69 yr, 
no previous prostate cancer, 
>5-yr prognosis if other 
cancer diagnosis
791 BRCA1 
carriers 
731 BRCA2 
carriers 
531 BRCA1 
controls* 
428 BRCA2 
controls* 
732 PSA <3 
ng/ml 
732 Annual PSA Follow-up
60 PSA  >3 
ng/ml 
18 Biopsy Cancer 
27 Biopsy  Benign
3 Biopsy Abnormal 
12 Declined Biopsy
479 PSA <3 
ng/ml 
479 Annual PSA Follow-up
52 PSA  >3 
ng/ml 
10 Biopsy Cancer 
33 Biopsy  Benign
0 Biopsy  Abnormal
9 Declined Biopsy
672 PSA <3 
ng/ml
672 Annual PSA Follow-up 
59 PSA  >3 
ng/ml 
24 Biopsy Cancer 
25 Biopsy Benign
1 Biopsy Abnormal
9 Declined Biopsy
400 PSA <3 
ng/ml 400 Annual PSA Follow-up
28 PSA  >3 
ng/ml 
7 Biopsy Cancer
14 Biopsy Benign 
0 Biopsy Abnormal
7 Declined Biopsy
BRCA1 Carrier Summary:      
• 7.6% required further  
   invesgaons                        
• 2.3% cancer incidence          
• 40.9% PPV of biopsy 
• 61.1% intermediate-/ 
 high-risk disease 
BRCA1 Control  Summary:      
• 9.8% required further  
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• 1.9% cancer incidence               
• 23.3% PPV of biopsy 
• 60.0% intermediate-/high-   
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BRCA2 Carrier  Summary:      
• 8.1% required further  
   invesgaons                             
• 3.3% cancer incidence               
• 48.0% PPV of biopsy  
• 68.0% intermediate-/high-     
   risk disease 
BRCA2 Control  Summary:      
• 6.5% required further  
   invesgaons                             
• 1.6% cancer incidence               
• 33.3% PPV of biopsy  
• 42.9% intermediate-/high-    
   risk disease 
Fig. 2 – Consort diagram for the first round of screening.
BRCA1 = breast cancer 1, early onset; BRCA2 = breast cancer 2, early onset; PSA = prostate-specific antigen; PPV = positive predictive value.
* Controls were men who had a negative predictive genetic test for the BRCA mutation in their family.
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Spearman correlation was used to determine the relationship between
PSA measurements taken in the clinical and laboratory settings.
3. Results
3.1. Study population
A total of 2481 participants from 62 centres in 20 countries
were recruited over 90 mo (Supplemental Table 1); there
were 791 BRCA1 carriers and 531 BRCA1 controls, as well as
731 BRCA2 carriers and 428 BRCA2 controls) (Fig. 2).
Themajority of participants werewhite (95%) and highly
educated (measured using self-reported qualifications), and
the mean age at enrolment was 54 yr (Table 1). Twenty-one
percent of the men reported urinary symptoms, and 37%
had previously had at least one PSA test. No statistically
significant differences were observed among groups; 27%
reported a family history of PCa in at least one blood
relative.
3.2. Prostate cancer detection rates at initial screening and
positive predictive value of biopsy
Of the 2481 men, 199 (8.0%) had PSA >3.0 ng/ml (range:
3.0–27.0; median: 4.3) and were referred to a urologist todiscuss prostate biopsy (Fig. 2). Of these men, 162 (81.4%)
underwent biopsy. Biopsies were declined because of
concurrent health conditions (n = 7), the urologist’s choos-
ing to repeat the PSA test prior to biopsy resulting in a
reading 3.0 ng/ml (n = 17), men changing their minds
(n = 8), or reason missing (n = 5). Fifty-nine of 162 biopsies
(36.4%) contained cancer. There was no significant differ-
ence in cancer detection rates betweenmenwho had or had
not undergone PSA screening prior to study entry. No
significant differences were seen with the Dutch cohort, in
which men with prior PSA screening were excluded. Other
than in the Dutch cohort, the prior screening levels were
similar in all countries.
The PCa detection rate was 2.4% (59 of 2481 men)
(Table 2). The detection rate for BRCA1 carriers was 2.3%
(18 of 791); it was 1.9% (10 of 531) for BRCA1 controls, 3.3%
(24 of 731) for BRCA2 carriers, and 1.6% (7 of 428) for BRCA2
controls, with no significant difference among groups.
The number of cores taken at biopsy ranged from 6 to 20;
however, there were no differences in the median or mean
number of cores taken among groups (Table 2). Four men
had either ASAP or HG PIN (all mutation carriers) (Table 2).
Two men underwent repeat biopsy with no cancers
detected. Taking potential geographical variation in cancer
incidence into consideration, the data were analysed by
region (North America; Australia; Asia; and Western,
Table 1 – Sociodemographic characteristics
BRCA1+ (n = 791) BRCA1 (n = 531) BRCA2+ (n = 731) BRCA2 (n = 428) Total cohort
Age group, yr, no. (%)
40–49 264 (33) 148 (28) 298 (41) 118 (28) 828 (33)
50–59 294 (37) 224 (42) 254 (35) 169 (40) 941 (38)
60–69 233 (30) 159 (30) 179 (25) 141 (33) 712 (29)
Qualiﬁcations, no. (%)
No qualiﬁcations 33 (4) 13 (2) 39 (5) 24 (6) 109 (4)
School to 16 105 (13) 59 (11) 116 (16) 43 (10) 323 (13)
School to 18/college degree 133 (17) 117 (22) 89 (12) 86 (20) 425 (17)
Technical/vocational qualiﬁcations 191 (24) 134 (25) 143 (20) 81 (19) 549 (22)
University graduate 273 (35) 179 (34) 267 (37) 145 (34) 864 (35)
Other 15 (2) 16 (3) 26 (4) 17 (4) 74 (3)
Unknown 41 (5) 13 (2) 51 (7) 32 (7) 137 (6)
Family history of prostate cancer, no. (%)
Yes 177 (22) 142 (27) 234 (32) 129 (30) 682 (27)
No 528 (67) 307 (58) 453 (62) 249 (58) 1537 (62)
Unknown 86 (11) 82 (15) 44 (6) 50 (12) 262 (11)
Ethnicity, no. (%)
Caucasian 750 (95) 514 (97) 695 (95) 410 (96) 2369 (95.5)
East Asian 3 (0.4) 1 (0.2) 3 (0.4) 1 (0.2) 8 (0.3)
North Asian 8 (1,0) 6 (1.1) 0 2 (0.5) 16 (0.6)
Caribbean 1 (0.1) 0 0 0 1 (0.0)
Aboriginal/Torres Strait Islander 1 (0.1) 0 1 (0.1) 0 2 (0.1)
Mixed white and Caribbean 5 (0.6) 2 (0.4) 2 (0.3) 1 (0.2) 10 (0.4)
Mixed white and Asian 3 (0.4) 0 0 0 3 (0.1)
Any other Asian background 0 0 1 (0.1) 0 1 (0.04)
Any other mixed background 3 (0.4) 1 (0.2) 1 (0.1) 0 5 (0.2)
Any other 15 (2) 7 (1) 22 (3) 5 (1) 49 (2)
Not given 2 (0.3) 0 6 (0.8) 9 (2) 17 (0.7)
BRCA1 = breast cancer 1, early onset; BRCA2 = breast cancer 2, early onset.
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cant differences were observed.
The PPV of biopsy using a PSA threshold of 3.0 ng/ml
(ie, the number of cancers detected divided by the number
of biopsies performed) was 36% (59 of 162) (Table 2).
Broken down by genetic status, the PPV in BRCA1 carriers
was 37.5% (18 of 48); in BRCA1 controls, 23.3% (10 of 43); in
BRCA2 carriers, 48.0% (24 of 50); and in BRCA2 controls,
33.3% (7 of 21). There was no statistically significant
difference among groups (Pearson chi-square test for
BRCA1, p = 0.14; for BRCA2, p = 0.26).
There was no significant difference between either
mean age at PCa diagnosis or PSA level among groups.Table 2 – Summary of outcomes for men with prostate-specific antige
BRCA1+ (n = 791) BRCA1 (n = 5
Men PSA >3.0 ng/ml, no. 60 52
Mean age, yr 60.1 59.8
Biopsy rate, % 7.6 9.8
Biopsies performed, no. 48 43
Biopsy–benign, no. 27 33
Biopsy–cancer, no. 18 10
Biopsy–ASAP/HG PIN, no. 3 0
No biopsy, no. 12 9
PPV of biopsy, % 37.5 23.3
Biopsy cores, no., median; mean (range) 10; 9.4 (6–13) 11; 10.3 (6–2
BRCA1 = breast cancer 1, early onset; BRCA2 = breast cancer 2, early onset; PSA =
high-grade prostate intraepithelial neoplasia; PPV = positive predictive value.Twelve men (20%) reported urinary symptoms prior to
diagnosis, and 20 men (34%) had a PSA test prior to study
entry (29% BRCA2 carriers, 50% BRCA2 controls; 44% BRCA1
carriers, 33% BRCA1 controls). There was no difference
observed in levels of PSA screening prior to study entry
among groups.
Using the NICE classification [31,34], intermediate- or
high-risk tumours were diagnosed in 11 of 18 BRCA1
carriers (61%) compared with 8 of 10 BRCA1 controls (80%)
and in 17 of 24 BRCA2 carriers (71%) compared with 3 of 7
BRCA2 controls (43%) (Table 3). There was no significant
difference observed between genetic status and disease risk
status. The PPV of biopsy using a PSA threshold of 3.0 ng/mln level >3.0 ng/ml
31) BRCA2+ (n = 731) BRCA2 (n = 428) Total cohort (n = 2481)
59 28 199
58.1 62.2 59.7
8.1 6.5 8.0
50 21 162
25 14 99
24 7 59
1 0 4
9 7 37
48.0 33.3 36.4
0) 10; 10.1 (5–12) 10; 10.1 (6–13) 10; 9.9 (5–20)
prostate-speciﬁc antigen; ASAP/HG PIN = atypical small acinar proliferation/
Table 3 – Clinical features of the prostate cancers at diagnosis
Patient Status Age,
yr
Disease risk
classiﬁcation
PSA test prior
to study entry
PSA,
ng/ml
Gleason
score
Clinical
stage
Treatment Family history
of prostate cancer
Urinary
symptoms
1 BRCA1+ 55 High Yes 5.9 4 + 4 pT2c Prostatectomy No No
2 BRCA1+ 69 High Yes 6.3 3 + 3 pT3b Prostatectomy No Yes
3 BRCA1+ 60 High Yes 3.3 3 + 3 pT3a Prostatectomy Yes No
4 BRCA1+ 59 High No 3.8 3 + 5 T3a * Yes No
5 BRCA1+ 61 Intermediate No 9.7 3 + 4 T1c Prostatectomy No No
6 BRCA1+ 61 Intermediate Yes 4.5 3 + 4 pT2c Prostatectomy Yes No
7 BRCA1+ 69 Intermediate Yes 7.4 3 + 3 T2b Radiotherapy Yes Yes
8 BRCA1+ 53 Intermediate No 3.9 3 + 3 T2 Prostatectomy No No
9 BRCA1+ 63 Intermediate No 4.2 3 + 3 pT2c Prostatectomy Yes No
10 BRCA1+ 49 Intermediate Yes 3.8 3 + 3 pT2c Prostatectomy No No
11 BRCA1+ 45 Intermediate No 3.2 3 + 4 T2b Prostatectomy Yes No
12 BRCA1+ 61 Low Yes 4.1 3 + 3 T1c Active surveillance No No
13 BRCA1+ 56 Low No 5.3 3 + 3 pT2a Prostatectomy Yes No
14 BRCA1+ 63 Low Yes 3.4 3 + 3 pT2a Prostatectomy No Yes
15 BRCA1+ 57 Low No 3.7 3 + 3 T1c Prostatectomy No No
16 BRCA1+ 64 Low No 5 3 + 3 T1c Active surveillance No No
17 BRCA1+ 64 Low No 6.2 3 + 3 T1c Active surveillance No No
18 BRCA1+ 48 Low No 5.3 3 + 3 * * No No
19 BRCA1 61 High Yes 7.7 4 + 3 pT3a Prostatectomy No No
20 BRCA1 62 High Yes 3.1 3 + 4 pT3a Prostatectomy Yes Yes
21 BRCA1 62 Intermediate No 3.3 3 + 3 pT2c Prostatectomy No No
22 BRCA1 61 Intermediate No 4.8 3 + 3 T2c Prostatectomy No Yes
23 BRCA1 66 Intermediate Yes 5.5 4 + 3 T1c Radiotherapy Yes No
24 BRCA1 57 Intermediate No 4.5 3 + 4 T2c Prostatectomy Yes Yes
25 BRCA1 55 Intermediate No 5.2 3 + 4 pT2 Prostatectomy No No
26 BRCA1 65 Intermediate No 4.7 3 + 3 pT2c Prostatectomy No No
27 BRCA1 59 Low No 4.3 3 + 3 T1c Active surveillance Yes No
28 BRCA1 62 Low Unknown 9.9 3 + 3 T1c Prostatectomy No No
29 BRCA2+ 66 High Yes 5 3 + 4/4 + 3 pT3a Prostatectomy No No
30 BRCA2+ 51 High No 27 4 + 3 pT3a Prostatectomy Yes No
31 BRCA2+ 66 High No 24 4 + 4 T4 Radiotherapy No No
32 BRCA2+ 66 High Yes 11 4 + 5 T3a Prostatectomy No No
33 BRCA2+ 61 High No 6.3 4 + 5 T1c Prostatectomy No No
34 BRCA2+ 67 High No 12.8 3 + 3 T3a Brachytherapy No No
35 BRCA2+ 62 High Yes 8.2 3 + 4 pT3a Prostatectomy Yes Yes
36 BRCA2+ 49 Intermediate Unknown 4.9 3 + 4 T2c Prostatectomy No No
37 BRCA2+ 68 Intermediate Yes 5.3 3 + 4 T2b Radiotherapy No No
38 BRCA2+ 54 Intermediate No 3.1 3 + 3 pT2c Prostatectomy No No
39 BRCA2+ 56 Intermediate No 5 3 + 4 pT2c Prostatectomy Yes No
40 BRCA2+ 59 Intermediate Yes 3 3 + 4 T2c Prostatectomy Yes No
41 BRCA2+ 58 Intermediate No 5.1 4 + 3 pT2c Prostatectomy No No
42 BRCA2+ 41 Intermediate No 3.5 3 + 4 pT2c Prostatectomy Yes Yes
43 BRCA2+ 65 Intermediate No 4.7 3 + 4 T1c Radiotherapy No No
44 BRCA2+ 53 Intermediate No 3.6 3 + 3 T2c Prostatectomy No No
45 BRCA2+ 63 Intermediate No 3.5 3 + 3 pT2c Prostatectomy Yes Yes
46 BRCA2+ 67 Low No 4.8 3 + 3 T2a Active surveillance No No
47 BRCA2+ 55 Low No 4.5 3 + 3 T1c Active surveillance Yes Yes
48 BRCA2+ 61 Low 3.6 3 + 3 T1c Brachytherapy No Yes
49 BRCA2+ 57 Low No 4.9 3 + 3 T1c Active surveillance No Yes
50 BRCA2+ 45 Low No 4.7 3 + 3 T1c Active surveillance No No
51 BRCA2+ 61 Low No 4.1 3 + 3 T1c Active surveillance No No
52 BRCA2+ 54 Low Yes 3.3 3 + 3 T1c Active surveillance Yes No
53 BRCA2 69 High No 14.3 4 + 3 T3 Radiotherapy No No
54 BRCA2 62 Intermediate No 4.8 3 + 4 pT2c Prostatectomy No No
55 BRCA2 65 Intermediate Yes 4.2 3 + 3 T1c Active surveillance No No
56 BRCA2 60 Low No 5.5 3 + 3 T1c Active surveillance No No
57 BRCA2 68 Low Yes 3.3 3 + 3 T1c Active surveillance No No
58 BRCA2 66 Low Yes 6.7 3 + 3 T2a Prostatectomy No No
59 BRCA2 53 Low Unknown 3.4 3 + 3 T2b Prostatectomy No No
BRCA1 = breast cancer 1, early onset; BRCA2 = breast cancer 2, early onset; PSA = prostate-speciﬁc antigen.
* Data pending.
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carriers and controls was 2.38% (17 of 714) and 0.71% (3 of
425), respectively; this difference is significant (Pearson
chi-square, p = 0.04). No significant differencewas observedin BRCA1 carriers compared with controls (1.41% [11 of 780]
compared with 1.33% [8 of 524]; Pearson chi-square test,
p = 0.86). No cases had nodal involvement or metastatic
disease at diagnosis.
Table 4 – Patient characteristics for kallikrein analysis*
Characteristics No cancer (n = 33) Cancer (n = 24)
BRCA1 tested, no. (%) 18 (55) 11 (46)
BRCA1+, no. (%) 10 (56) 10 (91)
BRCA2 tested, no. (%) 15 (45) 13 (54)
BRCA2+, no. (%) 12 (80) 10 (77)
Age at study entry, yr, median (quartiles) 59 (55, 64) 61 (57, 66)
Speciﬁc site total PSA, ng/ml, median (quartiles) 4.2 (3.4, 5.0) 4.4 (3.7, 5.2)
Central site total PSA, ng/ml, median (quartiles) 3.9 (3.4, 5.1) 4.2 (3.3, 5.4)
Free PSA, ng/ml, median (quartiles) 0.93 (0.73, 1.19) 0.83 (0.53, 0.96)
Intact PSA, ng/ml, median (quartiles) 0.53 (0.42, 0.69) 0.47 (0.31, 0.67)
hK2, ng/ml, median (quartiles) 0.051 (0.038, 0.076) 0.062 (0.036, 0.083)
MSP, ng/ml, median (quartiles) 19 (11, 26) 18 (11, 24)
Rotterdam score 0.235 (0.162, 0.310) 0.327 (0.243, 0.373)
Gleason total score, no. (%)
6 17 (71)
7 7 (29)
Clinical T stage, no. (%)
T1C 8 (33)
T2 2 (8.3)
T2A 1 (4.2)
T2B 2 (8.3)
T2C 3 (13)
T3 1 (4.2)
Unknown 7 (29)
BRCA1 = breast cancer 1, early onset; BRCA2 = breast cancer 2, early onset; PSA = prostate-speciﬁc antigen; hK2 = human kallikrein-related peptidase 2;
MSP = microseminoprotein.
* Data are frequency (percentage) or median (quartiles).
Table 5 – Univariate logistic regression for the outcomes of evidence of prostate cancer at biopsy and evidence of high-grade prostate cancer
at biopsy*
Predictor Odds ratio 95% CI p value
Total PSA, ng/ml (n = 57)
Cancer 1.02 0.75–1.37 0.9
High-grade cancer 1.49 1.00–2.23 0.051
Rotterdam score (n = 57)**
Cancer 2.30 1.25–4.22 0.007
High-grade cancer 3.87 1.42–10.60 0.008
MSP, ng/ml (n = 57)
Cancer 1.00 0.95–1.04 0.8
High-grade cancer 0.95 0.86–1.03 0.2
BRCA1 status (n = 29)+
Cancer 8.00 0.76–389.69 0.10
High-grade cancery 0.5
BRCA2 status (n = 28)+
Cancer 0.83 0.09–7.73 1
High-grade cancer 1.47 0.11–83.27 1
Mutation status (n = 57)+
Cancer 2.50 0.60–12.35 0.2
High-grade cancer 2.33 0.24–114.86 0.7
CI = conﬁdence interval; BRCA1 = breast cancer 1, early onset; BRCA2 = breast cancer 2, early onset; MSP = microseminoprotein; PSA = prostate-speciﬁc antigen.
* Subset of 57 men biopsied for whom an adequate serum sample was available.
** The odds ratio for the Rotterdam score corresponds to a 0.1-unit increase on a 0–1 probability scale.
+ The 95% CI and p values are calculated using the Fisher exact test.
y The odds ratio and 95% CI are not estimable because of zero events in the BCRA1-negative group. The p value is calculated from the chi-square test.
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kallikrein panel
There was a strong correlation between PSA values
measured in the clinical and laboratory settings (Spearman
r = 0.85). Serum samples of 57 (24 with PCa) of the 162men
who underwent a biopsy were analysed for MSP and four
kallikrein markers (Table 4).We found no association between PCa at biopsy and total
PSA orMSP (Table 5). We compared the proportion of PCa in
mutation carriers with controls and found no association
between PCa at biopsy and mutation status. There was an
association of PCa at biopsy and Rotterdam score (Wald test
p = 0.024). The discrimination of the Rotterdam model was
0.70 (95% confidence interval [CI], 0.56–0.84). For the
outcome of high-grade cancer, the Rotterdam score was the
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 4 8 9 – 4 9 9496only statistically significant predictor ( p = 0.009), with a
discrimination of 0.86 (95% CI, 0.73–0.99).
For 1202 of 2481 participants with available blood
samples, we found a strong correlation of total PSA between
measurements taken in the clinical and laboratory settings
(Spearman r = 0.95).
3.4. Serious adverse events
Six study-related serious adverse events were reported, all
occurring after biopsy. Complications occurred in 6 of 158
participants (3.8%), with five infections (3.2%) reported, two
requiring hospitalisation. The sixth participant was hospi-
talised because of fainting after biopsy.
4. Discussion
In this paper we have presented the results of the first
screening round of IMPACT, including the number and
features of the PCa detected. With germline mutations in
BRCA1 and BRCA2 being rare, the success of IMPACT has
been in the formation of an international consortium of
62 centres with both clinical genetics and urologic
collaboration. Enrolment was open until the required
number of recruits was obtained in all four cohorts,
exceeding the numbers required for statistical power in
all groups.
Compliance with the protocol was high, with 162 men
with PSA >3.0 ng/ml (>81%) proceeding to biopsy. This
number compares favourably with the 86% in the ERSPC
[35] and the 31.5% in the PLCO study [35–37]. In the PLCO
study, with no strict protocol to guide intervention, 74% of
men with an abnormal screening test underwent further
diagnostic evaluation, and 64% underwent biopsy within
3 yr [37]. Thus, a similar increase in compliance may be
anticipated in IMPACT at subsequent screening rounds.
The potential utility ofmultiparametricmagnetic resonance
imaging (MRI) as a screening tool before biopsy has been the
subject of recent debate [38]; however, the IMPACT protocol
was designed prior to the use of MRI in this diagnostic
capacity.
In total, 8%of themenhadapositivePSA test (>3.0ng/ml),
which is lower than the 16.2% (range: 11.1–22.3% among
sites) reported in the ERSPC general population screening
study [35]. However, the ERSPC recruited an older cohort
of men (55–75 yr), with a mean age of 61 yr compared with
54 yr in IMPACT. It is known that PSA increases with age, so
higher PSA levels would be expected. In addition, a number
of ERSPC centres used a threshold of 4.0 ng/ml rather than
3.0 ng/ml to determine biopsy, so the two studies are not
entirely directly comparable. These results indicate that
overbiopsy is not a concern in this younger cohort.
There is controversy about the PSA level used to trigger
biopsy, with no clear consensus. The results presented show
that while not statistically significant, the PPV of biopsy
using a PSA threshold of 3.0 ng/ml is higher for BRCA2
carriers than for controls (48% vs 33%) and higher for BRCA1
carriers than controls (41% vs 23%). For BRCA2 carriers, this
percentage is double the 24.1% reported in the ERSPCgeneral population sample. This higher PPV observed in
mutation carriers may be explained, at least in part, by the
fact that the ERSPC screened older men. Also, given the
younger age of the IMPACT cohort, the incidence of benign
prostatic hypertrophy (BPH) may have been lower; the
incidence of BPH increases with age, and BPH lowers the
specificity of PSA screening [27,39,40]. These data suggest
that lowering the PSA threshold for biopsy in BRCA2 carriers
could potentially detect early-stage disease, thus reducing
the need for more toxic treatments and ultimately reducing
PCa mortality. However, this lowering would need to be
balanced against the risk of potentially life-threatening
side-effects of biopsy [41,42].
In IMPACT, men will be offered a prostate biopsy at the
end of the study (at the centres with the capacity), which
may provide evidence for the optimal PSA threshold for
detecting clinically significant PCa in this cohort of higher-
risk men.
The observed differences in PPV may also reflect the
higher incidence and grade of PCa previously reported,
particularly in BRCA2 carriers. The higher PPV in BRCA2
carriers suggests that PSA may have a higher specificity in
this high-risk setting. However, as the number of cancers is
relatively small, subsequent PSA screening rounds are
essential to confirm this hypothesis. Evaluation of the panel
of four kallikrein markers in subsequent screening rounds
may provide further insights into the panel’s potential role
in predicting biopsy outcome [30].
The ERSPC reported that 4.2% of men had a cancer
diagnosis at the first screening round [43]. In IMPACT, the
PCa detection rate was 2.4%, and two-thirds of the men in
the cohort were previously unscreened. The younger age of
the IMPACT sample is likely to explain this lower detection
rate. More than two-thirds of the PCa detected in the BRCA2
carriers were classified as intermediate – or high – risk,
supporting retrospective reports of a more aggressive
phenotype and poorer prognosis in this group [7–12].
Sixty-one percent of BRCA1 carriers were classified as
having intermediate- or high-risk disease. By comparison,
in the ERSPC, only 27.8% of the PCa diagnosed in the
screened cohort were Gleason score 7 [35]. Longer-term
follow-up will determine whether there is a difference in
metastatic events and mortality between carriers and
controls. From the PLCO study, after 13 yr of follow-up,
there is no evidence to support the idea that organised PSA
screening reduces mortality compared with opportunistic
screening [14]. In contrast, after amedian of 11 yr of follow-
up, the ERSPC reported a 21% reduction in PCa-specific
mortality in the screened cohort [15]. It is important to note
that in the PLCO, 56% of men in the control arm had PSA
screening, compared with 15% in the ERSPC.
The higher incidence of clinically significant disease in
the BRCA2mutation carriers, together with the significantly
younger age of BRCA2 carriers with PSA >3.0 ng/ml, is an
important observation in view of the younger age of this
cohort compared with the ERSPC study. The only cancers
detected in men <50 yr were in BRCA1 and BRCA2 carriers.
These data add to the increasing evidence that BRCA1/2
carriers develop more aggressive disease, and at a younger
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intermediate- or high-risk disease compared with the
ERSPC. However, the number of cancers is relatively small,
and with 19% of men declining biopsy, these data should be
interpreted with caution.
The population incidence of PCa in each of the recruiting
countries must be considered. The incidence in the
majority of the countries is very similar, except in India
and Malaysia [44]. Given the relatively low number of
recruits from these regions, geographical variation is
unlikely to have a major impact on the results. A limitation
of IMPACT is that 95% of the men were white. Thus, the
results cannot be generalised to all ethnic groups known to
have a higher risk of PCa and a more aggressive phenotype
(eg, black). A second limitation is that 37% of the cohort had
previously had a PSA test. This fact could potentially bias
the study to either having men with a lower PSA or having
men with higher PSAs due to noncancerous causes.
However, no difference in screening levels was observed
among those men with and without cancer. A further
limitation is that the control group was recruited from
families known to have BRCA mutations. It is possible that
this group of men has a different PCa risk profile than the
general population.
5. Conclusions
The first screening round of IMPACT demonstrates that
targeted screening for PCa in men with a genetic predis-
position detects clinically significant disease. Using a PSA
threshold of 3 ng/ml results in a low biopsy rate (8.0%) and a
high PPV, particularly in BRCA2 carriers, for the detection of
intermediate- and high-risk disease. Although the observed
differences in PCa detection rates between carriers and
controls was not statistically significant, the trend is clear.
With larger numbers of PCa in the follow-up phase (5 yr),
these differences, if sustained, are likely to be significant.
Future screening rounds will determine the optimal
frequency of PSA testing, determine the utility of PSA
screening in BRCA1 carriers, and provide further data on the
value of annual screening in BRCA2 carriers.
A previously published statistical model based on four
kallikrein markers was able to predict biopsy outcome in
participants with PSA >3 ng/ml with a discrimination of
0.86 for high-grade disease. Longer-term follow-up will be
used to validate the role of the kallikrein panel in this
population.
IMPACT is the first prospective study to demonstrate the
use of germline genetic markers to identify men at higher
risk of PCa, which has the potential to enable better risk
stratification to inform targeted screening. These early
results indicate that the tumours detected aremore likely to
need treatment based on national guidelines for manage-
ment of more aggressive PCa. Therefore, our preliminary
results support the use of PSA screening for BRCA2 carriers.
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